Trypanosoma brucei and T. vivax: salicylhydroxamic acid and glycerol treatment of acute and chronically infected rats.
In rats infected with monomorphic Trypanosoma brucei brucei, the efficacy of the therapy with salicylhydroxamic acid plus glycerol, i.e., combined therapy, decreased with increasing time after infection. It failed completely after the infection was made chronic by suboptimal treatment for 6 weeks. When this chronic infection had been established and "optimal" treatment was given, viable trypanosomes could still be detected 1 day later in brain and muscle but not in blood. In most organs, the concentrations of salicylhydroxamic acid and glycerol were lower than in the blood plasma; the maximum concentration of glycerol in the brain was only 20% of that in plasma. The most likely explanation for the failure of the combined therapy is that, in certain tissues, the concentration of the drugs remains too low to kill extravascular trypanosomes. Other explanations, such as the selection of a resistant strain or the survival of (extravascular) forms with a more active mitochondrion, could be excluded with a high degree of probability. Suramin was very effective, even after combined therapy had failed repeatedly, while melarsoprol was less effective. As in combined therapy, the dose of melarsoprol that could cure an acute infection was insufficient to cure a chronic infection. Combined therapy failed after a spontaneous chronic infection with T. b. rhodesiense had existed for 5-7 weeks, but it was effective in T. vivax infected rats even when parasitemia had been present for at least 4 days. Effective alternative schedules for combined therapy were not found.
D000818:Animals; D001921:Brain / Q000469:parasitology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005990:Glycerol / Q000008:administration & dosage / Q000627:therapeutic use*; D008549:Melarsoprol / Q000008:administration & dosage / Q000627:therapeutic use; D051379:Mice; D009132:Muscles / Q000469:parasitology; D051381:Rats; D011919:Rats, Inbred Strains / Q000469:parasitology; D012457:Salicylamides / Q000008:administration & dosage / Q000627:therapeutic use*; D013498:Suramin / Q000008:administration & dosage / Q000627:therapeutic use; D014344:Trypanocidal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D014345:Trypanosoma / Q000187:drug effects; D014346:Trypanosoma brucei brucei / Q000187:drug effects; D014352:Trypanosomiasis / Q000188:drug therapy*; D014353:Trypanosomiasis, African / Q000188:drug therapy*
D012457:Salicylamides; D014344:Trypanocidal Agents; D013498:Suramin; C005703:salicylhydroxamic acid; D005990:Glycerol; D008549:Melarsoprol